EU/3/19/2188

About

On 21 August 2019, orphan designation EU/3/19/2188 was granted by the European Commission to ORPHELIA Pharma S.A.S, France, for temozolomide for the treatment of neuroblastoma.

Key facts

Active substance
temozolomide
Disease / condition
Treatment of neuroblastoma
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2188

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Orphelia Pharma S.A.S.
85 Boulevard Saint Michel
75005 Paris
France
Tel: +33(0)1 42 77 08 18
E-mail: contact@orphelia-pharma.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating